The pathogenesis of psoriasis can be explained by dysregulation of immunological cell function as well as keratinocyte proliferation/differentiation. Recently, the immunological pathomechanism has been clarified substantially. Whereas T-helper (Th)1 overactivation was thought to induce occurrence of psoriasis, it has been demonstrated that Th17 cells play a key role. Th17 development is maintained by interleukin (IL)-23 mainly produced by dendritic cells. Th17 cells produce various cytokines, including IL-17A, IL-17F and IL-22. IL-17A and IL-22 induce not only keratinocyte proliferation, but also tumor necrosis factor (TNF)-a, chemokine (C-X-C motif) ligand (CXCL)1 and CXCL8 production. TNF-a accelerates the infiltration of inflammatory cells, including lymphocytes, monocytes and neutrophils, from the peripheral blood into skin with dendritic cell activation. In addition, antimicrobial peptides are overexpressed in psoriatic skin lesions, and the antimicrobial peptide, LL-37, activates dendritic cells, which leads to the development of inflammation. Furthermore, activation of nuclear factor-jB signal induces the expression of keratins 6 and 16 in keratinocytes, which are associated with acanthosis and reduced turnover time in the epidermis. The progression of the pathomechanism contributes to the development of new therapies for psoriasis.
INTRODUCTION
Psoriasis affects approximately 2% of the world's population, but its rate in Japan is 0.1-0.2%. [1] [2] [3] [4] This difference may be attributable to racial factors. The occurrence is affected by various factors, including a heritable predisposition, environmental factors, endocrine hormones and immunological factors. Recent studies have improved our understanding of the pathogenesis of psoriasis, and facilitated the development of new drugs targeting various molecules thought to be involved. This review summarizes current knowledge and information regarding the pathogenesis of psoriasis.
PATHOMECHANISM OF PSORIASIS AS AN IMMUNE DISEASE T-helper 1/2
In 1979, it was reported that cyclosporin A (CsA) improved psoriatic skin eruptions, which suggested that the pathology of psoriasis is related not only to keratinocytes but also to the immune system. 5 Activated CD4 + and CD8 + lymphocytes were initially considered to be equally important in the inflammation associated with psoriasis because large numbers of activated CD4 + and CD8 + lymphocytes were identified in the skin and peripheral blood of psoriatic patients. 6, 7 Subsequently, CD4 + T-helper (Th) were shown to play a more important role than CD8 + lymphocytes, because psoriasis-like skin lesions developed in mice transplanted with activated Th cells from psoriatic patients. 8, 9 Moreover, the levels of Th1 cytokines, such as c-interferon (IFN-c), tumor necrosis factor-a (TNF-a) and interleukin (IL)-12, were elevated in psoriatic lesions, while no such increases in expression of Th2 cytokines (IL-4, IL-5 and IL-10) were observed. [10] [11] [12] These findings characterized psoriasis as a Th1-type disease. However, keratinocyte proliferation is not induced by IFN-c or TNF-a, either. [13] [14] [15] The pathogenesis of psoriasis could not be fully understood based only on Th1 functions, and it was predicted that other key players should participate in its occurrence.
Th17 and Th17 cytokines
The close relation between IL-17 and psoriasis was reported. High levels of IL-17 mRNA were detected in psoriatic lesional skin, but not in non-lesional skin. 25 In keratinocytes, IL-17 enhanced the expression of IL-6 and IL-8, which are known as pro-inflammatory cytokines and exacerbate psoriasis. 26 In addition, topical application of imiquimod, a Toll-like receptor (TLR)7/8 ligand and potent immune activator, induced psoriasis-like dermatitis in mice together with the expression of IL-17A and IL-17F. 27 Furthermore, both CsA and anti-TNF-a agents decreased the levels of IL-17A, IFN-c, IL-23p19 and chemokine (C-C motif) ligand 20 in psoriatic lesions in conjunction with improvement of psoriatic eruptions, indicating that pro-inflammatory cytokines, including IL-17A, are involved in the development of psoriasis. 26, [28] [29] [30] These findings suggest that the IL-17 family plays an important role in psoriasis.
Interleukin-22, a member of the IL-10 cytokine family, 31, 32 is closely related to psoriatic inflammation (Fig. 1) . IL-22 is mainly produced by Th17 cells. T22, which produces only IL-22, has also been identified. The functional IL-22 receptor is chiefly expressed on keratinocytes, and IL-22 induces epidermal hyperplasia by enhancing keratinocyte proliferation. IL-22 in the peripheral blood is also elevated in patients with psoriasis compared with healthy subjects. 33 IL-22 expression is increased in the psoriatic skin lesions and conversely decreased in association with remission by antipsoriatic therapy. 33 These findings suggest that IL-22 promotes keratinocyte proliferation and plays important roles in the pathology of psoriasis.
Dendritic cells, IL-23 and TNF-a
Interleukin-23 was discovered in a study searching for members of the IL-6 cytokine family. 34 The role of IL-23 in cutaneous inflammation has been investigated in both humans and mice. In humans, IL-23p19 and IL-12p40 (IL-12/23p40) were shown to be overexpressed in psoriatic skin lesions, and most of the IL-23p19 was produced by mature DC, monocytes and monocyte-derived DC in the papillary dermis. 40 In mice, IL-23 was shown to mediate acanthosis and hyperkeratosis through the increased production of TNF-a, IL-12p40 (IL-12/23p40), IL-23p19 and IL-20R2 (IL-20 receptor subunit). 41, 42 DC is the main source of IL-23 in psoriatic skin lesions. Dendritic cells are antigen-presenting cells, and play a role in regulating differentiation of naive T cells to mature T cells. When activated, DC migrate from the skin into draining lymph nodes to present antigens and activate T-cell responses. 43 TNF and inducible nitric oxide synthase-producing DC (Tip-DC) are increased in psoriatic lesions, 44 and produce large amounts of TNF-a. Tumor necrosis factor-a plays a pivotal role in the pathogenesis of psoriasis (Fig. 1) . 45 TNF-a activates the nuclear factor (NF)-jB signal pathway, which affects cell survival, proliferation and anti-apoptotic effects of lymphocytes and keratinocytes. [46] [47] [48] In addition, TNF-a stimulates keratinocytes to produce IL-8, which leads to microabscess formation by enhancing neutrophil recruitment in psoriasis. 49 TNF-a induces Th17 to produce pro-inflammatory cytokines through the NF-jB pathway in psoriatic lesions, and blockade of the NF-jB pathway results in a loss of IL-17A production from CD4 + T cells. 50 TNF-a activity is elevated in psoriatic lesions, and TNF inhibitors cure the inflammatory condition in psoriatic lesions. 
PATHOMECHANISM OF DYSKERATOSIS
The epidermis is composed of a basal layer, spinous layer, granular layer and cornified layer. The transit time of keratinocytes from the basal layer to the spinous layer is reduced from approximately 13 days in the normal epidermis to only 48 h in psoriatic lesions. 52 It was also reported that the cell cycle was shortened from 311 h in normal lesions to 36 h in basal keratinocytes of psoriatic lesions, indicating substantial acceleration of keratinocyte proliferation in psoriatic lesions. 53 The pathomechanism underlying psoriasis is considered to involve the acceleration of cell proliferation and the rapid migration of keratinocytes from the basal layer to the granular layer. Keratinocyte proliferation is regulated by several molecules, such as cyclic antimicrobial peptide (AMP), protein kinase C, phospholipase C and transforming growth factor-a. 54 Keratin expression is also altered in the psoriatic epidermis. The differentiation-specific keratins 1 and 10, which are chiefly expressed in the spinous layers are decreased, while keratins 6 and 16 are increased in the psoriatic epidermis. 55 In addition, involucrin, transglutaminase 1 and keratin 17 are increased, whereas profilaggrin is decreased in psoriatic skin. 55, 56 These findings show that the cytoskeletal protein profile is altered in the psoriatic epidermis. Psoriasis is characterized as a disorder of proliferation and differentiation in keratinocytes.
As described above, the psoriatic skin has very specific characteristics with regard to differentiation and proliferation of keratinocytes. The goal of psoriasis treatment is to control the differentiation and proliferation of keratinocytes. Treatments directly targeting keratinocytes seem to address these issues without direct risk of infection, unlike treatments that regulate the immune system. Retinoids and vitamin D are therapeutic methods that mainly target keratinocytes. Further analyses of the mechanisms underlying epidermal cell regulation are necessary.
PSORIASIS AND ANTIMICROBIAL PEPTIDES
Antimicrobial peptides are found in a variety of organisms, including mammals, insects and plants. AMP are composed of 12-50 amino acids, and play roles in host defense via killing pathogens, such as bacteria, protozoa, fungi and some viruses. 57, 58 Furthermore, they affect inflammatory responses by acting as chemotactic agents, angiogenic factors and regulators of cell proliferation. Various AMP, such as b-defensins, S100 proteins and cathelicidin, are highly expressed in psoriatic lesions. 57, 58 It was suggested that these AMP may play important roles in psoriasis. The defensins, a family of cationic microbial peptides divided into three categories, namely defensins a, b and h, contain six conserved cystein residues that form three pairs of intramolecular disulfide bonds. 57, 59 The a-defensins are further divided into six subtypes designated as human neutrophil peptides (HNP) 1-6, of which HNP 1-3 are present in the scales of psoriatic lesions. 60 b-Defensins are divided into four subtypes designated as human b-defensins (hBD) 1-4. hBD 2-3 are expressed at high levels in psoriatic scales, and are induced by TNF-a and IFN-c in keratinocytes. 61, 62 In addition, hBD 2 is also induced by IL-17A and IL-22. The copy numbers of individual b-defensins are associated with genetic influences of predisposition for psoriasis. 63 The S100 proteins are a family of low molecular weight (9-13-kDa) proteins characterized by the presence of two calcium binding sites in helix-loop-helix motifs. 58, 64 Twenty-one S100
proteins have been isolated to date, 13 of which are expressed in both the normal and psoriatic epidermis. S100A7 (psoriasin), S100A8 (calgranulin A), S100A9 (calgranulin B), S100A12 (calgranulin C) and S100A15 are abundantly expressed in psoriatic lesions, and some are elevated in the serum of psoriatic patients. 59 Interestingly, keratinocytes, treated with combinations of IL-22, IL-17A and IL-17F, showed induced expression of S100A9 with additively enhanced expression of S100A7 and S100A8. 65 S100A7 may also have a chemotactic potential in psoriasis. 66 Cathelicidins are also AMP, and one of the cathelicidins, LL-37, is associated with the development of psoriasis. 67 The LL-37 highly expressed in the psoriatic epidermis may accelerate inflammation through its capacity to enable plasmacytoid DC to recognize self-DNA via TLR9. 68 In addition, type I IFN, which is expressed at high levels in psoriatic skin, is induced by stimulation with LL-37 and DNA. 69 These observations suggest the relation of the AMP with the pathomechanism of psoriasis.
GENERALIZED PUSTULAR PSORIASIS AND RELATED GENES
Studies of twins and families with psoriasis suggested that this disease is a multifactorial genodermatosis. 70 The concordance rate of monozygotic twins is approximately 70% compared with approximately 20% for dizygotic twins. 71 Furthermore, genome-wide association studies with large cohorts have clarified the genetic aspects of psoriasis. Many genes involved in predisposition to psoriasis have been found, including HLACw6, ERAP1, IL12Bp40, IL23Ap19, IL4, IL13 and TNFAIP3.
72,73
However, these genes do not substantially predispose people to psoriasis. On the other hand, several genetic mutations have been shown to markedly influence the occurrence of generalized pustular psoriasis (GPP). Generalized pustular psoriasis is a variant of psoriasis, and characterized by fever, general fatigue and dehydration, and is triggered by many factors, including systemic infection, pregnancy, hypocalcemia associated with hypothyroidism, and drugs. 74 The accumulation of intraepidermal and subcorneal neutrophils in clusters called Kogoj's spongiform pustules suggests accelerated activation of neutrophils in GPP.
IL36RN
In 2011, deficiency of IL36RN was found in an autosomal recessive type of familial GPP, and IL36RN was noted as a causative gene for GPP in 2011. 75 IL36RN encodes IL-36 receptor antagonist (IL36Ra), which suppresses the function of IL-36 (IL-36a, IL-36b and IL-36c) belonging to the IL-1 family. All three IL-36 subtypes are highly expressed in psoriatic lesions, and are robust inducers of neutrophil chemokines, including chemokine (C-X-C motif) ligand (CXCL)1 and CXCL8. 76, 77 Deletion of the mouse ortholog of IL36RN, Il1f5, was also shown to lead to a skin phenotype similar to GPP in mice. 78 Neutrophilic activation in GPP is likely developed by increased IL-36 activity due to dysfunction of IL36Ra (Fig. 3) .
CARD14
Caspase recruitment family member 14 (CARD14, also known as CARMA2) is a conserved scaffold protein that mediates TNF receptor-associated factor 2 (TRAF2)-dependent activation of NF-jB signaling. Several gain-of-function mutations in CARD14, such as p.Gly117Ser, have been identified in GPP.
79-83

AP1S3
AP1S3 encodes a subunit of AP-1, which is a transcription factor that regulates the expression of keratins in keratinocytes. AP1S3 mutations were identified in GPP patients, 84 and may induce IL-1b, IL-36 and CXCL8 expression through dysfunction of NF-jB signaling.
TREATMENT STRATEGY FOR PSORIASIS BASED ON ITS PATHOGENESIS Retinoids
Retinoids, namely vitamin A and related compounds, have been used to treat eruptions in psoriasis since the early 1980s. Retinoids affect gene transcription via binding to two distinct families of nuclear receptors, retinoic acid receptors (RAR) and retinoid X receptors (RXR), 85 which are ligandactivated transcription factors that bind to retinoid hormone response elements in the promoter regions of target genes, including IL-6. 86 Retinoids improve the symptoms of psoriasis by regulating not only cell proliferation/differentiation but also inflammation. The pro-inflammatory cytokines IL-6 and migration inhibition factor-related protein 8 are decreased through RAR binding.
87
The third-generation retinoid, tazarotene, has been approved for use in the USA and Europe as a therapeutic agent for psoriasis, which has fewer side-effects than previous retinoid agents. 88 Etretinate is the only retinoid approved by the health insurance system in Japan for the treatment of psoriasis. However, etretinate shows teratogenicity 89 and accumulates in the body for a long period. Acitretin, a pharmacologically active derivative of etretinate, is used in other countries because it has a shorter elimination half-life. 90 
Vitamin D
Vitamin D plays important roles in the maintenance of skin homeostasis. Photochemical cleavage of 7-dehydrocholesterol to form vitamin D takes place in the skin and requires minimal exposure to ultraviolet B to generate physiological quantities of the product. 91 Vitamin D binds to its receptor, inducing many events in the cell. The vitamin D receptor (VDR) is a phosphopeptide with a molecular weight of approximately 60 kD. VDR is a member of the nuclear receptor transcriptional factor superfamily, similar to RAR and RXR. The VDR acts preferentially as a heterodimer with the RXR on specific DNA sequences in the promoter regions of vitamin D target genes.
Vitamin D affects not only keratinocyte proliferation and differentiation but also inhibit immune response, improving symptoms of psoriatic patients. 91 In psoriatic skin, vitamin D increases the expression of Bcl-xL and induces apoptosis of keratinocytes.
92
In addition, vitamin D possesses immunomodulatory activities. In vitro, vitamin D inhibits the production of IL-8 and regulated and normal T-cell expressed and secreted (RANTES) and upregulates expression of the receptor for the anti-inflammatory cytokine, IL-10, in keratinocytes. 93, 94 Vitamin D also inhibits monocyte differentiation into DC 95 and lymphocyte activation by promoting the release of IL-2.
96,97
PDE4 inhibitor
Phosphodiesterase (PDE) degrades the intracellular phosphodiesterase bonds of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDE4 is an isoenzyme with predominant cAMP degradation activity, and is expressed in most immune cells, including lymphocytes, granulocytes and monocytes/macrophages, as well as epithelial cells. 98 The intracellular second messenger, cAMP, inhibits the NF-jB pathway directly or via phosphorylation of cAMP response element binding protein (CREB) (Fig. 4) . 99 As the NFjB pathway is activated in psoriasis, cAMP stabilization due to PDE4 inhibition alleviates inflammation of psoriasis by suppression of the NF-jB signal. 100 Apremilast, a selective PDE4 inhibitor, has been approved for the treatment of psoriasis.
99,101
CsA Cyclosporin A (CsA) was a key agent for the treatment of severe psoriasis until the development of biologics, and CsA is still an important medication for psoriasis. 102 CsA improves psoriatic inflammation by inhibiting T-cell activation. T-cell receptor activation by antigen binding induces an increase in intracellular calcium level, which activates calcineurin by binding of calcium with calmodulin. Activated calcineurin dephosphorylates the cytoplasmic portion of the nuclear factor of activated T cells (NFAT c ), leading to translocation of NFAT c into the nucleus and induction of transcription of IL-2 and several other cytokines.
CsA forms a complex with cyclophilins, thus blocking NFAT c dephosphorylation, cytokine production and T-cell infiltration. 103 Cyclosporin A is highly effective, although it is associated with a number of side-effects, including hypertension, nephrotoxicity and hepatotoxicity. In addition, CsA carries an increased risk of the development of lymphoproliferative disorders and other malignancies. 104, 105 It is recommended that long-term treatment with CsA is desirable until 2 years in Europe. the IL-17 pathway, which is related to psoriasis. Therefore, the rates of patients attaining at least 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI)-75 and PASI-90 were extremely high in previous studies of other biologics, and the effect was expressed rapidly. [107] [108] [109] [110] [111] [112] Anti-IL23p19 antibody formulation for clinical use is in the final stages of development, and it has also been reported to be very effective. 113 For reference, the biologics approved in Japan are outlined in Table 1 .
CONCLUSION
The pathogenesis of psoriasis involves various cell types, including inflammatory cells and keratinocytes, as well as antimicrobial peptides. Additional basic studies regarding the pathogenesis will lead to the further development of therapeutic agents for psoriasis.
